• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Neuroendocrine Tumors Drug Pipeline Update 2014 Product Image

Neuroendocrine Tumors Drug Pipeline Update 2014

  • ID: 1196710
  • July 2014
  • Region: Global
  • Bioseeker

There are today 78 companies plus partners developing 86 neuroendocrine tumor drugs in 125 developmental projects in cancer. In addition, the accumulated number of ceased drugs over the last years amount to another 16 drugs. Neuroendocrine Tumors Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 81 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 79 out of the 80 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 28 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.

How May Drug Pipeline Update Be of Use?
- Show investors/board/management that you are right on top of drug development progress in your therapeutic area. * Find competitors, collaborations partners, M&A candidates etc. * Jump start competitive READ MORE >



Delivery Format: Desktop App plus Online Access to Updates (One Year)

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos